Table 3.
Role of different two-component systems involved in mediating antibiotic resistance in response to acid stress. All abbreviations are listed at the end of the manuscript.
| Treatment under Acid Stress |
Two-Component Systems Involved |
Acquired Antibiotic Resistance/Tolerance |
Phenotypic Expression 1 |
Reference |
|---|---|---|---|---|
| ΔtatC, over-expressed nlpE | CpxRA | Cationic antimicrobial peptides (CAPs) | Increased tolerance | [145] |
| ΔrcsF, ΔrcsB, ΔcpxR | RcsCB, CpxRA | Mecillinam and cefsulodin | Increased tolerance | [139] |
| ΔcpxR | CpxRA | Cephalexin | Increased tolerance | [156] |
| W3110 tolC732::kan, W3110 acrB747::kan, W3110 mdtB774::kan, W3110 mdtF769::kan, W3110 emrY776::kan, W3110 emrB767::kan, W3110 marR751::kan |
MarRAB, AcrAB, EmrKY, MdtABC and TolC |
Extended-spectrum β-lactamases (ESBLs) | Increased tolerance | [152] |
| Δmar | MarRAB, AcrAB and TolC |
Beta-lactamase, rifampicin, spectinomycin, streptomycin, tetracycline, nalidixic acid | Increased resistance | [157] |
| ΔrcsF and ΔrcsB | RcsBC | Cefsulodin | Increased tolerance | [139] |
| RcsBC, CpxRA, BaeSR |
Mecillinam and cefsulodin | |||
| baeR cloned pTrc99A plasmid | BaeRS, MdtABC, ArcAB |
Ceftriaxone, | 8 fold increased resistance | [158,159] |
| novobiocin, | ||||
| deoxycholate | ||||
| pH stress only | ArcAB, MarRAB | Ceftriaxone, | Presence ofhyper-resistantcolonies | [60] |
| amikacin, | ||||
| nalidixic acid | ||||
| ArcAB, MarRAB, MdtABC | Multidrugresistance | [144,160] | ||
| RcsCB | Cationic antimicrobial peptides (CAPs) | Intrinsic resistance | [161] | |
| Aztreonam | [162] | |||
| Beta-lactams | [161] | |||
| Daptomycin | [96,163,164] | |||
| ΔdpiA, ΔcpxR | RcsBC, CpxRA | Ampicillin | Increased tolerance | [165] |
| ΔpmrA, ΔpmrB | PmrAB, arn operon | PolymyxinB | Increased tolerance | [137] |
| ΔacrB | BaeSR, RcsBC, CpxRA, EvgAS, ArcAB |
Multidrug resistance |
16- to 32-fold increased resistance | [166] |
| ΔmarR | MarRAB | Norfloxacin | Increased tolerance | [44]. |
| ΔacrBΔevgAS, ΔacrBΔemrKY, ΔacrBΔyhiUVΔemrKY, ΔacrBΔyhiUVΔemrKY/pUCevgA | ArcAB, EvgAS, EmrKY | Multidrug resistance |
4 fold increased resistance | [167,168] |
| Overexpression of baeR, evgA, rcsB | BaeSR, RcsBC, CpxRA, EvgAS, ArcAB |
Multidrug resistance |
16- to 32-fold increased resistance | [166] |
1 Resistance is an increase in MIC above the breakpoint; tolerance is the loss of killing with no change in MIC.